Simavita releases progress update - Seite 2

In line with the Company's mission, we have delivered the following major milestones. These milestones are in addition to the financial results of the Company for the First Quarter which will be reported shortly and include:

Product:

AssessPLUS, Simavita's first totally new product, will deliver simple and cost effective management and assessment of incontinence for new and major markets including Community Care and the disabled living at home. AssessPLUS is in its final stages of pilot customer reviews and acceptance testing. AssessPLUS was identified in May 2016 as part of the change management process, specified, developed and has been delivered on schedule and within budget.

AssessPLUS has been designed to be a cost effective "out of the box" incontinence assessment and management solution for carers operating within the National Disabilities Insurance Scheme and for carers looking after the elderly in their own homes. We envisage that AssessPLUS will deliver an extremely easy to use solution, designed to reduce the cost of incontinence whilst dramatically improving the quality of life for those suffering from incontinence. Our clear experience is that those people using Simavita Incontinence Management solutions regain confidence to socialise, improve hydration and reduce hospital visits through the reduction or elimination of falls, urinary tract infections and skin problems.

Our existing incontinence solution for institutional use, SIM™ Version 4.12, was delivered in July 2016 to existing users and incorporates improved intuitive reporting, enhanced user interface on the SIM™ tablet and support for multiple facilities per server. These significant enhancements greatly assist our aged care group customers.

Simavita has developed a clear and ongoing product road map for the rapid delivery of new product to areas of significant and unmet need in the field of smart, wearable and disposable sensors for the health care industry.

European update:

Market expansion in Europe is progressing ahead of schedule:

• We have strengthened our relationship with Abena and, as a consequence, extended sales in Denmark
• OneMed has been appointed as a distributor for The Netherlands and Sweden and assessments have commenced
• A distributor has been identified to cover the southern region of Germany
• Negotiations are advanced with a Spanish distributor

A land mark multi-centre clinical trial across 2 countries has been agreed with University of Maastricht in The Netherlands and Ghent University in Belgium to start early in the new year.